Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Phase III randomized trial of volasertib combined with low-dose cytarabine (LDAC) versus placebo plus LDAC in patients aged >= 65 years with previously untreated, acute myeloid leukemia (AML) ineligible for intensive remission induction therapy

DeAngelo, Daniel J., Sekeres, Mikkael A., Ottmann, Oliver ORCID: https://orcid.org/0000-0001-9559-1330, Sanz, Miguel A., Naoe, Tomoki, Taube, Tillmann, Belsack, Valerie, Ge, Miaomiao and Doehner, Hartmut 2015. Phase III randomized trial of volasertib combined with low-dose cytarabine (LDAC) versus placebo plus LDAC in patients aged >= 65 years with previously untreated, acute myeloid leukemia (AML) ineligible for intensive remission induction therapy. Clinical Lymphoma, Myeloma and Leukemia 15 , S194-S194. 10.1016/j.clml.2015.04.046

Full text not available from this repository.
Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Subjects: R Medicine > R Medicine (General)
Publisher: Elsevier
ISSN: 2152-2650
Last Modified: 02 Nov 2022 09:54
URI: https://orca.cardiff.ac.uk/id/eprint/96773

Actions (repository staff only)

Edit Item Edit Item